The reorganization will allow Sanofi to refocus its R&D on cancer, immunology, rare diseases and vaccines. The company will end cardiology research.
Job cuts are voluntary. France has powerful unions that often challenge job cuts if they aren’t voluntary, according to the report.
More articles on pharmacy:
Lupin recalls 18,408 bottles of antibiotic in US
Bluebird Bio prices gene therapy at $1.8M
10 hospitals seeking pharmacy leaders
